State of Wyoming Has $513,000 Holdings in Qiagen N.V. $QGEN

Key Points

• The State of Wyoming increased its stake in Qiagen N.V. by 358.2%, owning a total of 12,775 shares worth $513,000 after acquiring an additional 9,987 shares in the first quarter.
• Qiagen's recent earnings report showed an EPS of $0.60, meeting analysts’ expectations, with revenues up 7.7% year-over-year at $533.54 million.
• Several analysts have recently adjusted their price targets for Qiagen, with Bank of America raising its target from $50.00 to $53.00, indicating a positive outlook for the stock.

State of Wyoming raised its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 358.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,775 shares of the company's stock after purchasing an additional 9,987 shares during the period. State of Wyoming's holdings in Qiagen were worth $513,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. SVB Wealth LLC purchased a new stake in Qiagen in the first quarter worth $31,000. ANTIPODES PARTNERS Ltd purchased a new stake in Qiagen in the first quarter worth $94,000. Tower Research Capital LLC TRC grew its stake in Qiagen by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC boosted its position in Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Qiagen during the 1st quarter worth approximately $150,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on QGEN. Barclays began coverage on Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price for the company. Cowen reaffirmed a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Bank of America lifted their price objective on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Wall Street Zen downgraded Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Finally, UBS Group lifted their price objective on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, Qiagen currently has a consensus rating of "Hold" and an average target price of $49.69.

Qiagen Trading Up 0.8%

QGEN stock traded up $0.38 during midday trading on Friday, reaching $47.42. 436,712 shares of the company traded hands, compared to its average volume of 1,390,031. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The firm has a market capitalization of $10.54 billion, a price-to-earnings ratio of 28.02, a P/E/G ratio of 2.47 and a beta of 0.64. The business has a 50 day moving average of $48.66 and a 200-day moving average of $44.30. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same quarter in the prior year, the firm posted $0.55 EPS. Qiagen's quarterly revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, sell-side analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.